Tech Company Financing Transactions
Terremoto Biosciences Funding Round
On 5/25/2022, Terremoto Biosciences raised $75 million in Series A financing from OrbiMed and Third Rock Ventures.
Transaction Overview
Company Name
Announced On
5/25/2022
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series A
Investors
OrbiMed (Lead Investor) (Peter Thompson)
Third Rock Ventures (Lead Investor) (Reid Huber)
Proceeds Purpose
The financing will be used to advance Terremoto's lysine-targeted covalency platform and develop best-in-class therapies against known drug targets, as well as first-in-class medicines against the previously undruggable.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1700 Owens St
San Francisco, CA 94158
USA
San Francisco, CA 94158
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
The world has witnessed incredible advances in drug development over the last two decades, including new drugs for previously intractable targets. And yet, many patients still face too few treatment options, notably in devastating conditions like cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Thompson
Browse more venture capital transactions:
Prev: 5/25/2022: Natrion venture capital transaction
Next: 5/25/2022: Shellworks venture capital transaction
Share this article
News on VC Transactions
We do our best to document all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs